glp 1 vs glucagon Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight GLP-1R and Diabetes
Description
doi:10.1056/NEJMoa2206038 97
World j Diabetes
The semaglutide withdrawal symptoms add another layer to the stopping equation
Wan J, Ferrari C, Tadros M
The jury is out at the moment, but their potential to be differentiated from injectable peptides is clear and seems likely to drive significant research into small molecule modulators of GLP-1 for the treatment of diabetes, obesity and perhaps addictive behaviours for many years to come.
Ganio says
